At a glance
ClinicalIndex Comparison RecordN/ACompleted· 300 target
Drug / intervention
solu medrol +1 moredrug
Likely dose
solu medrol 20mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Liver Transplantation Results in Hepatocellular Carcinoma Patients With Immunosuppression Without Steroids
Shanghai Jiao Tong University School of Medicine·interventional·Posted Jun 4, 2010·Updated Jun 4, 2010
In Brief
A clinical study evaluating solu medrol and a steroid-free immunosuppression protocol for Immunosuppression and 3 related conditions. Completed, enrolled 300 participants across 1 site.
Detailed Summary
The purpose of this study was to evaluate the safety and efficacy of a steroid-free immunosuppression protocol in Hepatocellular Carcinoma (HCC) patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsImmunosuppression, Hepatocellular Carcinoma, Liver Transplantation, Post-operative Complications
CountriesChina
Timeline
N/ACompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2005
Primary CompletionJan 2008
Study CompletionDec 2009
First PostedJun 2010
TodayJul 2026
First PostedJun 4, 2010
Enrollment StartJan 1, 2005
Primary CompletionJan 1, 2008
Study CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 16.1 years ago
Interventions
solu medroldrug
total dose 20mg/kg, including first dose 10mg/kg, rest of drug given within one weeks after liver transplantation
a steroid-free immunosuppression protocoldrug
receive immunosuppression with Basiliximab(20mg/day,twice following transplantation) and tacrolimus(0.06/kg/d,twice a day) without steroids.